Phenotypes Associated with This Genotype

Genotype
MGI:5425617

• Allelic Composition: Gpx4^tm1.1Qra/Gpx4^tm1.1Qra; Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

lethality, complete penetrance ( J:183246 )

• all mice die within 2 weeks of the 4th injection of tamoxifen (4 injections administered over an 8 day period)

growth/size/body

cachexia ( J:183246 )

• starting after 3 injections of tamoxifen in mice at 6 - 9 months of age

• becomes significant 1 week after the 4th injection of tamoxifen

cellular

astrocytosis ( J:183246 )

• elevated astrocyte activation in the hippocampal region 1 week after the last tamoxifen injection

increased hepatocyte apoptosis ( J:183246 )

• 1 week after the last tamoxifen injection

abnormal cellular respiration ( J:183246 )

• enhanced lipid peroxidation and impaired electron transport chain activity and ATP production in mitochondria 1 week after the last tamoxifen injection

behavior/neurological

lethargy ( J:183246 )

• seen in tamoxifen treated mice shortly before death

nervous system

astrocytosis ( J:183246 )

• elevated astrocyte activation in the hippocampal region 1 week after the last tamoxifen injection

neurodegeneration ( J:183246 )

• in the hippocampal region 1 week after the last tamoxifen injection

liver/biliary system

increased hepatocyte apoptosis ( J:183246 )

• 1 week after the last tamoxifen injection